The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...
Welcome to the Crinetics Pharmaceuticals Corporate Update Conference Call. [Operator Instructions] I will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Thank ...
The diagnosis of polycystic ovary syndrome, a common hyperandrogenic disorder, requires the exclusion of several diseases that might show similar symptoms at presentation, for example nonclassical ...
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs.
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 ...
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced PALSONIFY U.S. unaudited and preliminary net product revenue of over $5 million for ...
A high proportion of cases of congenital adrenal hyperplasia (CAH) are attributable to deficiency of 21-hydroxylase, which results in presentation of ambiguous genitalia at birth in girls but with no ...
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback